Pneumococcal polysaccharide vaccine
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i

superseded


Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)

Pneumococcal polysaccharide vaccine

  • Published Date:

    February 10, 1989

  • Source:
    MMWR. Morbidity and mortality weekly report. 1989; 38(5):64-8, 73-6.
  • Language:
    English
Filetype[HTM]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 317.21 KB]
    Personal Author:
    Levine, Orin S. ; Schwartz, Benjamin ; ...
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; ...
    Published Date:
    October 6, 2000
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 49, no. RR-9 PMID:11055835:MODS 11055835
    Description:
    In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (Prevnar, marketed by Wyeth Lederle Vaccines) was licensed for use ...
    File Type:
    Filetype[PDF - 317.21 KB]
    File Type:
    Filetype[PDF - 317.21 KB]
  2. Filetype[PDF - 317.21 KB]
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    10/06/2000
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2000; 49(RR-9):1-35.
    Description:
    In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (Prevnar, marketed by Wyeth Lederle Vaccines) was licensed for use ...
    Status:
    superseded
    File Type:
    Filetype[PDF - 317.21 KB]
    File Type:
    Filetype[PDF - 317.21 KB]
  3. Filetype[PDF - 271.87 KB]
    Personal Author:
    Rodenburg, Gerwin D. ; de Greeff, Sabine C. ; ...
    Published Date:
    May 2010
    Source:
    Emerg Infect Dis. 16(5):816-823.
    Description:
    In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program fo...
    File Type:
    Filetype[PDF - 271.87 KB]
    File Type:
    Filetype[PDF - 271.87 KB]
  4. Filetype[PDF - 366.74 KB]
    Personal Author:
    Nelson, George E. ; Gershman, Kenneth A. ; ...
    Published Date:
    Feb 2012
    Source:
    Emerg Infect Dis. 18(2):208-216.
    Description:
    Pneumococcal pneumonia was a complication during previous influenza pandemics but was not evident initially during pandemic (H1N1) 2009. During Octobe...
    File Type:
    Filetype[PDF - 366.74 KB]
    File Type:
    Filetype[PDF - 366.74 KB]
  5. Filetype[PDF - 1.35 MB]
    Personal Author:
    Davidson, Michael ; Chamblee, Carol ; ...
    Published Date:
    1993 Jul-Aug
    Source:
    Public Health Rep. 108(4):439-446
    Description:
    In response to an increasing prevalence of serious pneumococcal disease among adult Alaska Natives of northwest Alaska, a 3-year program was begun in ...
    File Type:
    Filetype[PDF - 1.35 MB]
    File Type:
    Filetype[PDF - 1.35 MB]